OptiPharm (Korea) Performance
| 153710 Stock | 4,775 50.00 1.06% |
The company holds a Beta of -0.0334, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning OptiPharm are expected to decrease at a much lower rate. During the bear market, OptiPharm is likely to outperform the market. At this point, OptiPharm has a negative expected return of -0.31%. Please make sure to check OptiPharm's maximum drawdown, potential upside, and the relationship between the treynor ratio and value at risk , to decide if OptiPharm performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days OptiPharm Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
OptiPharm |
OptiPharm Relative Risk vs. Return Landscape
If you would invest 577,000 in OptiPharm Co on August 27, 2024 and sell it today you would lose (99,500) from holding OptiPharm Co or give up 17.24% of portfolio value over 90 days. OptiPharm Co is generating negative expected returns and assumes 1.3094% volatility on return distribution over the 90 days horizon. Simply put, 11% of stocks are less volatile than OptiPharm, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
OptiPharm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for OptiPharm's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as OptiPharm Co, and traders can use it to determine the average amount a OptiPharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2381
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 153710 |
Estimated Market Risk
| 1.31 actual daily | 11 89% of assets are more volatile |
Expected Return
| -0.31 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.24 actual daily | 0 Most of other assets perform better |
Based on monthly moving average OptiPharm is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of OptiPharm by adding OptiPharm to a well-diversified portfolio.
Things to note about OptiPharm performance evaluation
Checking the ongoing alerts about OptiPharm for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for OptiPharm help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| OptiPharm generated a negative expected return over the last 90 days |
- Analyzing OptiPharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether OptiPharm's stock is overvalued or undervalued compared to its peers.
- Examining OptiPharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating OptiPharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of OptiPharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of OptiPharm's stock. These opinions can provide insight into OptiPharm's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for OptiPharm Stock analysis
When running OptiPharm's price analysis, check to measure OptiPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OptiPharm is operating at the current time. Most of OptiPharm's value examination focuses on studying past and present price action to predict the probability of OptiPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OptiPharm's price. Additionally, you may evaluate how the addition of OptiPharm to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| CEOs Directory Screen CEOs from public companies around the world |